Myths vs facts: CYP2C19 and Stress

The claim that your CYP2C19 genotype directly determines how well you handle stress is a myth. CYP2C19 is a drug-metabolizing enzyme primarily involved in breaking down medications such as clopidogrel, proton pump inhibitors, and certain antidepressants (e.g., escitalopram, citalopram). There is no strong scientific evidence that CYP2C19 variants directly affect stress resilience or perceived stress. A fact, however, is that metabolic phenotype (ultrarapid, extensive, intermediate, poor) can indirectly influence the efficacy and side-effect profile of SSRIs used for stress-related disorders. For example, poor metabolizers are at higher risk of adverse effects at standard doses. But this does not mean they are 'genetically more stressed.' Most direct-to-consumer tests linking CYP2C19 to stress overstate clinical relevance. Stress is multifactorial – environment, lifestyle, psychosocial factors, and many other genes play far larger roles. Knowing your CYP2C19 status is useful only in the context of medication guidance by a physician, not as a 'stress gene' interpretation.